Under the agreement, Particle Sciences will be the exclusive contract research provider in the US for SoluBest's Solumer technology.

Particle Sciences will offer Solumer formulation and clinical trial supply manufacturing to Pharmaceutical and Biotech companies. The patented Solumer approach utilizes GRAS polymers to create drug/polymer complexes that result in greatly improved drug solubility and bioavailability.

According to Particle Sciences, once formulations come in contact with aqueous media, they spontaneously form colloidal dispersions, resulting in increased bioavailability of the active pharmaceutical ingredient. The process is easily adaptable to a wide range of molecules, making it attractive for both new chemical entities and life-cycle management challenges.

Amir Zalcenstein, CEO of SoluBest, said: “We are thrilled to partner with Particle Sciences. They are at the cutting edge of drug delivery technologies and provide us with greater access to the US marketplace.

“Additionally, by leveraging their significant GMP/GLP infrastructure, we are able to offer potential licensees a clear development path with a world-class CRO. Moreover, following our recent licensing deal with Dr. Reddy's, we're seeing a lot of interest in our technology, and partnering with Particle Sciences is essential in order to meet the increased demand.”

Mark Mitchnick, CEO of Particle Sciences, said: “The Solumer technology fits perfectly with our growth strategy of adopting truly value added drug delivery approaches to our portfolio. This is a proven technology that is both cost effective and scalable. It will find application with both NCE's and generics.

“Under this agreement, Particle Sciences will use Solumer technology to develop drug products for our clients. We are very excited to be working with SoluBest and are already evaluating the technology for specific projects.”

Will the agreement benefit the firms?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.